ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) – Analysts at HC Wainwright raised their Q3 2026 earnings estimates for ImmunityBio in a research report issued to clients and investors on Friday, May 8th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($0.07) for the quarter, up from their prior forecast of ($0.08). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for ImmunityBio’s Q4 2026 earnings at ($0.05) EPS and FY2027 earnings at $0.06 EPS.
ImmunityBio (NASDAQ:IBRX – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.54). The business had revenue of $44.21 million for the quarter, compared to analysts’ expectations of $43.07 million.
View Our Latest Research Report on ImmunityBio
ImmunityBio Stock Performance
Shares of NASDAQ:IBRX opened at $8.11 on Tuesday. The firm has a market cap of $8.49 billion, a PE ratio of -9.54 and a beta of 0.02. The firm’s fifty day moving average is $7.95 and its 200-day moving average is $5.26. ImmunityBio has a 52 week low of $1.95 and a 52 week high of $12.43.
Insider Activity
In other news, Director Barry J. Simon sold 75,000 shares of the business’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total transaction of $900,750.00. Following the completion of the sale, the director directly owned 2,850,821 shares of the company’s stock, valued at $34,238,360.21. The trade was a 2.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 275,000 shares of company stock valued at $2,934,500. 69.48% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. boosted its stake in ImmunityBio by 579.3% in the first quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock valued at $44,000 after acquiring an additional 4,907 shares during the last quarter. Archer Investment Corp boosted its stake in ImmunityBio by 67.1% in the first quarter. Archer Investment Corp now owns 5,872 shares of the company’s stock valued at $45,000 after acquiring an additional 2,358 shares during the last quarter. Slow Capital Inc. purchased a new position in ImmunityBio in the third quarter valued at about $25,000. Hodges Capital Management Inc. purchased a new position in ImmunityBio in the first quarter valued at about $77,000. Finally, Aaron Wealth Advisors LLC purchased a new position in ImmunityBio in the first quarter valued at about $78,000. 8.58% of the stock is currently owned by hedge funds and other institutional investors.
Key Headlines Impacting ImmunityBio
Here are the key news stories impacting ImmunityBio this week:
- Positive Sentiment: Founder Patrick Soon-Shiong highlighted potential commercial progress in Saudi Arabia and Greece for Anktiva, and said a Turkey launch could be next, signaling some non-U.S. growth opportunities for ImmunityBio. Article title
- Positive Sentiment: The company also teased development of an AI-driven “cancer cell robot,” suggesting continued long-term R&D ambitions that could support the pipeline narrative if execution improves. Article title
- Neutral Sentiment: Analysts are reassessing ImmunityBio’s outlook after the first-quarter report, with the latest coverage focused on how much the company can grow from here rather than on any immediate operational surprise. Article title
- Negative Sentiment: Multiple law firms are reminding investors about a May 26 lead-plaintiff deadline tied to a securities class action, extending the legal overhang on the shares. Article title
- Negative Sentiment: New and repeated shareholder alerts claim the lawsuit stems from alleged misleading cancer-claim disclosures following an FDA warning letter, which is weighing on investor sentiment. Article title
- Negative Sentiment: HC Wainwright reportedly cut its FY2028 EPS estimate, reinforcing concerns that profitability may take longer to arrive. Article title
ImmunityBio Company Profile
ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.
Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.
Further Reading
- Five stocks we like better than ImmunityBio
- TMC Forges a New EV Supply Chain at the Bottom of the Sea
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
